news

 

Top Indian dealmaker Shishir Vayttaden (L) has left the equity partnership at Cyril Amarchand Mangaldas to join Khaitan & Co, along with two other partners in his team, K. Aishwarya and Aditi Singhvi.

Vayttaden and Singhvi will be joining Khaitan’s Mumbai office, while Aishwarya joins in Bengaluru.

Vayttaden was one of CAM’s top M&A partners and regular counsel to the Reliance group, J&J, Abbott Labs, and Prudential Financial. He also regularly acts for the largest private equity funds active in India, such as Blackstone, KKR, and Warburg Pincus.

Haigreve Khaitan, senior partner at Khaitan & Co, said, “We are delighted to welcome Shishir and his team to our corporate and M&A practice. Shishir’s significant experience in dealmaking will further enhance our capabilities in delivering exceptional legal services to our clients. I am confident that their integration into our firm will be seamless, and they will contribute meaningfully to our continued success.”

Earlier this month, Khaitan added two employment partners from IndusLaw, and in April, it doubled the partner strength in its newly opened Ahmedabad office.

 

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Top CAM dealmaker rocks market with move to Khaitan

by Nimitt Dixit |

Top Indian dealmaker Shishir Vayttaden has left the equity partnership at Cyril Amarchand Mangaldas to join Khaitan & Co, along with two other partners in his team, K. Aishwarya and Aditi Singhvi.

White & Case guides $380mln U.S.-Japan LNG deal

by Nimitt Dixit |

Global law firm White & Case has advised Japan Petroleum Exploration Co. (JAPEX) on the acquisition through its U.S. subsidiary of an equity interest in Gulf Coast LNG Holdings, which owns an interest in the Freeport LNG project in Texas, from JERA Americas for approximately $380 million.

Reed Smith, Freshfields, Kirkland on Henlius’ $691 mln take-private deal

Freshfields Bruckhaus Deringer is representing Hong Kong-listed biotech company Henlius on its $691 million take-private deal offer from Shanghai Fosun New Medicine Research Company, which is being advised by Reed Smith.